Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00975182 · ClinicalTrials.gov registry record · Phase 1
A Study of the Safety and Pharmacology of GDC-0941 in Combination With Erlotinib in Patients With Advanced Solid Tumors
A Phase 1 study of Non-Squamous Non-Small Cell Lung Cancer, Solid Cancers, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
- 4
- Study locations
NCT00975182: Completed Phase 1 study of Non-Squamous Non-Small Cell Lung Cancer, Solid Cancers, sponsored by Genentech.
NCT00975182 is a Phase 1 study of Non-Squamous Non-Small Cell Lung Cancer, Solid Cancers that has completed, run by Genentech. The registered enrollment target is 58 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00975182, a Phase 1 study of Non-Squamous Non-Small Cell Lung Cancer, Solid Cancers, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is an open-label, multicenter, Phase Ib dose-escalation study to assess the safety, tolerability, and pharmacokinetics (PK) of oral (PO) GDC-0941 administered in combination with PO erlotinib in patients with advanced solid tumors and patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have failed at least one prior chemotherapy regimen.
Conditions Studied
Interventions
- DRUG GDC-0941
- DRUG erlotinib HCl
Study Locations (4)
Other
- - Amsterdam
- - Utrecht
Colorado
- - Aurora
New Jersey
- - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2009-09 |
| Est. Completion | 2014-09 |
| Phase | Phase 1 |
What the finished NCT00975182 record still lists
NCT00975182 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 1 condition, with Non-Squamous Non-Small Cell Lung Cancer, Solid Cancers appearing as the primary indexed condition, and to 2 interventions - of which GDC-0941 is the first listed.
NCT00975182 reports a single indexed study location in Other, Colorado, New Jersey.
Frequently Asked Questions
What is clinical trial NCT00975182 about?
NCT00975182 is a clinical study titled "A Study of the Safety and Pharmacology of GDC-0941 in Combination With Erlotinib in Patients With Advanced Solid Tumors". This is an open-label, multicenter, Phase Ib dose-escalation study to assess the safety, tolerability, and pharmacokinetics (PK) of oral (PO) GDC-0941 administered in combination with PO erlotinib in patients with advanced solid tumors and patients with locally advanced or metastatic non-small cell ...
What is the current status of trial NCT00975182?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2009-09. Estimated completion is 2014-09.
What conditions does trial NCT00975182 study?
This clinical trial studies the following conditions: Non-Squamous Non-Small Cell Lung Cancer, Solid Cancers.
What interventions are being tested in trial NCT00975182?
The interventions under investigation include: GDC-0941 (DRUG), erlotinib HCl (DRUG).
Who is sponsoring clinical trial NCT00975182?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00975182 being conducted?
This trial has 4 study locations across Colorado, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00975182's enrollment target sits among peer trials
58 895th of 2000 higher than 1,100 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia